The attached poster was presented at COG (Children’s Oncology Group) in September, 2018, at JADPRO Live 2018 (www.APSHO.org) in November, 2018 in Ft Lauderdale, and then again at SAYAO (Society for Adolescent and Young Adult Organization) in Newport, CA in November, 2018. It is reprinted here with the kind permission of Dr. Faina Shenderov, Joe DiMaggio Children’s Hospital, San Diego, CA.

The key finding: The results of this retrospective small patient study showed that using Oncaspar attached to a “Y” infusion set with normal saline decreased clinical Adverse Reactions 18% to 1.6%. The patients experienced a significant improvement in the quality of life as well as a reduction in the need to switch to the alternate drug, Erwinaze™.